Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (161-170 of 221) with videos related to

Pageof 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 20, 2010
Amplification of epidermal growth factor receptor gene in renal cell carcinomaIman El-Hariry, Thomas Powles, Mike R Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Predictors of early death risk in older patients treated with first-line chemotherapy for cancerPierre Soubeyran, Marianne Fonck, Christèle Blanc-Bisson, et al.
Angiogenesis|October 19, 2012
The experimental renal cell carcinoma model in the chick embryoPatricia Fergelot, Jean-Christophe Bernhard, Fabienne Soulet, et al.
Clinical Genitourinary Cancer|June 12, 2016
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT TrialsPetri Bono, Stephane Oudard, Istvan Bodrogi, et al.
Clinical Genitourinary Cancer|March 7, 2019
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 ExpressionSolène-Florence Kammerer-Jacquet, Angelique Brunot, Mathilde Lefort, et al.
Urologic Oncology|June 17, 2017
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatmentSolène-Florence Kammerer-Jacquet, Angelique Brunot, Karim Bensalah, et al.
BJU International|November 5, 2013
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 studyFlorence Joly, Remy Delva, Loïc Mourey, et al.
Clinical Pharmacokinetics|March 17, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal ImpairmentChristian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, et al.
British Journal of Clinical Pharmacology|April 1, 2020
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairmentChristian Rolfo, Nicolas Isambert, Antoine Italiano, et al.
Targeted Oncology|May 28, 2017
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line TherapySolène-Florence Kammerer-Jacquet, Sarah Medane, Karim Bensalah, et al.
Pageof 23

Showing results (161-170 of 221) with videos related to

Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|February 20, 2010
Amplification of epidermal growth factor receptor gene in renal cell carcinomaIman El-Hariry, Thomas Powles, Mike R Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Predictors of early death risk in older patients treated with first-line chemotherapy for cancerPierre Soubeyran, Marianne Fonck, Christèle Blanc-Bisson, et al.
Angiogenesis|October 19, 2012
The experimental renal cell carcinoma model in the chick embryoPatricia Fergelot, Jean-Christophe Bernhard, Fabienne Soulet, et al.
Clinical Genitourinary Cancer|June 12, 2016
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT TrialsPetri Bono, Stephane Oudard, Istvan Bodrogi, et al.
Clinical Genitourinary Cancer|March 7, 2019
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 ExpressionSolène-Florence Kammerer-Jacquet, Angelique Brunot, Mathilde Lefort, et al.
Urologic Oncology|June 17, 2017
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatmentSolène-Florence Kammerer-Jacquet, Angelique Brunot, Karim Bensalah, et al.
BJU International|November 5, 2013
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 studyFlorence Joly, Remy Delva, Loïc Mourey, et al.
Clinical Pharmacokinetics|March 17, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal ImpairmentChristian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, et al.
British Journal of Clinical Pharmacology|April 1, 2020
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairmentChristian Rolfo, Nicolas Isambert, Antoine Italiano, et al.
Targeted Oncology|May 28, 2017
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line TherapySolène-Florence Kammerer-Jacquet, Sarah Medane, Karim Bensalah, et al.
Pageof 23